Targeting Ferroptosis as an Advance Strategy in Cancer Therapy
Antioxidants & Redox Signaling · 2024-10 · 41 (10-12) · 616-636
DOI: 10.1089/ars.2024.0608 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Antioxidants & Redox Signaling, online erschienen am 22.10.2024. Verfasst von Tobias Achu Muluh und 9 weiteren Autor:innen. Beteiligte Einrichtung: Shenzhen University Medical School, Shenzhen University, Shenzhen, China. Hauptthemen laut MEDLINE: Ferroptosis, Neoplasms, Tumor Microenvironment. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 204 Literaturangaben.
Abstract (Originalsprache)
Significance: This study innovates by systematically integrating the molecular mechanisms of iron death and its application in cancer therapy. By deeply analyzing the interaction between iron death and the tumor microenvironment, the study provides a new theoretical basis for cancer treatment and directions for developing more effective treatment strategies. In addition, the study points to critical issues and barriers that need to be addressed in future research, providing valuable insights into the use of iron death in clinical translation. Recent Advances: These findings are expected to drive further advances in cancer treatment, bringing patients more treatment options and hope. Through this paper, we see the great potential of iron death in cancer treatment and look forward to more research results being translated into clinical applications in the future to contribute to the fight against cancer. Critical Issues: In today’s society, cancer is still one of the major diseases threatening human health. Despite advances in existing treatments, cancer recurrence and drug resistance remain a severe problem. These problems increase the difficulty of treatment and bring a substantial physical and mental burden to patients. Therefore, finding new treatment strategies to overcome these challenges has become significant. Future Directions: The study delved into the molecular basis of iron death in tumor biology. It proposed a conceptual framework to account for the interaction of iron death with the tumor immune microenvironment, guide treatment selection, predict efficacy, explore combination therapies, and identify new therapeutic targets to overcome cancer resistance to standard treatments, peeving a path for future research and clinical translation of ferroptosis as a potential strategy in cancer therapy. Antioxid. Redox Signal. 41, 616–636.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Shenzhen University Medical School, Shenzhen University, Shenzhen, China.
- Shanghai Waker Bioscience Co., Ltd., Shanghai, China.
- Clinical Research Center, The First Affiliated Hospital of Shantou University Medical College, Shantou, China.
- Marshall Laboratory of Biomedical Engineering, Shenzhen University Medical School, Shenzhen University, Shenzhen, China.
ORCID-Profile: Tobias Achu Muluh
Zitieren
APA
Muluh, T. A., Fu, Q., Ai, X., Wang, C., Chen, W., Zheng, X., Wang, W., Wang, M., Shu, X. S., & Ying, Y. (2024). Targeting Ferroptosis as an Advance Strategy in Cancer Therapy. Antioxidants & Redox Signaling, 41(10-12), 616-636. https://doi.org/10.1089/ars.2024.0608
Vancouver
Muluh TA, Fu Q, Ai X, Wang C, Chen W, Zheng X, et al. Targeting Ferroptosis as an Advance Strategy in Cancer Therapy. Antioxidants & Redox Signaling. 2024;41(10-12):616-636. doi:10.1089/ars.2024.0608
BibTeX
@article{Muluh2024,
author = {Muluh, Tobias Achu and Fu, Qianqian and Ai, Xiaojiao and Wang, Changfeng and Chen, Wei and Zheng, Xiangyi and Wang, Wei and Wang, Maolin and Shu, Xing-Sheng and Ying, Ying},
title = {Targeting Ferroptosis as an Advance Strategy in Cancer Therapy},
journal = {Antioxidants & Redox Signaling},
year = {2024},
volume = {41},
number = {10-12},
pages = {616--636},
doi = {10.1089/ars.2024.0608}
}
EUVIMED